Abstract Most patients with acquired pure red cell aplasia (PRCA) and some with acquired aplastic anemia (AA) respond well to cyclosporine (CsA), but thereafter often show CsA dependency. The mechanism underlying this dependency remains unknown. We established a reliable method for measuring the regulatory T cell (Treg) count using FoxP3 and Helios expression as markers and determined the balance between Tregs and other helper T cell subsets in 16 PRCA and 29 AA patients. The ratios of interferon-γ-producing CD4 + (Th1) T cells to Tregs in untreated patients and CsAdependent patients were significantly higher (PRCA 5.77 ± 1.47 and 7.38 ± 2.58; AA 6.18 ± 2.35 and 8.94 ± 4.06) than in healthy volunteers (HVs; 3.33 ± 0.90) due to the profound decrease in the percentage of Tregs. In contrast, the ratios were comparable to HVs in convalescent CsA-treated AA patients (4.74 ± 2.10) and AA patients in remission after the cessation of CsA treatment (4.24 ± 1.67). Low-dose CsA (100 ng/ml) inhibited the proliferation of conventional T cells (Tconv) to a similar degree to the inhibition by Tregs in a co-culture with a 1:1 Treg/Tconv ratio. The data suggest that CsA may reverse the hematopoietic suppression in PRCA and AA patients by compensating for the inadequate immune regulatory function that occurs due to a profound decrease in the Treg count.
Introduction
Idiopathic pure red cell aplasia (PRCA) is a refractory erythropoietic failure that is characterized by the absence of erythroblasts in the bone marrow (BM) with normal white blood cell and platelet counts. Although the exact cause is unclear, various effector mechanisms have been proposed, including CD8 + T cells, γδT cells, large granular lymphocytes, antierythropoietin antibodies, and anti-erythropoietin receptor antibodies [1] [2] [3] [4] [5] [6] . Despite the various immune mechanisms that underlie erythroid progenitor cell suppression, most PRCA patients respond to cyclosporine (CsA), an immunosuppressant which selectively suppresses T cells. Even more characteristically, PRCA patients show a strong dependency on CsA: they usually require low dose CsA to maintain good erythropoietic function [7] . This is in sharp contrast to the response to CsA in patients with idiopathic aplastic anemia (AA), most of whom can be withdrawn from CsA after achieving remission with antithymocyte globulin (ATG) and CsA therapy [8] . The similar dependency on CsA for hematopoietic function is observed in a subset of AA patients, particularly those who possess DRB1*15:01 [9] . The reason the strong CsA dependency on PRCA patients and this subset of AA patients remains to be elucidated. CD4 + CD25 + regulatory T cells (Tregs) play an important role in maintaining the homeostasis of the immune Electronic supplementary material The online version of this article (doi:10.1007/s00277-016-2629-7) contains supplementary material, which is available to authorized users.
system by suppressing autoreactive T cell induction and function. Tregs effectively control the development and progression of autoimmune diseases such as type 1 diabetes and psoriasis [10, 11] . Patients with immune-mediated BM failure such as AA have been shown to have significantly reduced numbers of Tregs [12, 13] . However, it is unclear whether the decrease in the Treg count is actively involved in BM suppression through the failure to control autoreactive T cells in these diseases because the BM failure syndromes affect both myelopoiesis and lymphopoiesis; thus, the decrease in Tregs may merely represent T lymphocytopenia which occurs due to a decrease in the number of hematopoietic stem cells. The role of Tregs in the development of immune-mediated BM failure may become clearer by studying patients with PRCA, in whom lymphopoiesis is not affected by causal mechanisms which selectively inhibit erythroid progenitors.
To test this hypothesis, we determined the percentage and absolute count of Tregs as well as helper T cell (Th) subsets, including Th1, Th2, and Th17 cells, in the peripheral blood (PB) of PRCA and AA patients, using an anti-FoxP3 antibody (Ab) and an anti-Helios Ab. This method allows for the functional Tregs to be enumerated more precisely than by conventional methods.
Materials and methods

Patients
Sixteen PRCA patients (idiopathic, n = 12; thymoma-associated, n = 3; and large granular lymphocytic leukemia [ LGL], n = 1) and 29 AA patients (non-severe AA, n = 22; and severe AA, n = 7) who were referred to our clinic from 2014 to 2015 and responded to CsA or CsA plus rabbit ATG (Thymoglobulin, Sanofi, Japan) therapy were included in this retrospective analysis. Among the 16 PRCA patients, 2 were untreated and 14 were undergoing CsA therapy after showing a good response to CsA (n = 10) or on CsA dependency (n = 4) at the time of blood sampling ( Table 1) . Nine of the AA patients were untreated (severe, n = 3; non-severe, n = 6), 5 of the AA patients were in the convalescent phase and undergoing CsA therapy, 6 showed CsA dependency, and 9 were remission after the cessation of CsA therapy. A total of 47 agematched healthy volunteers (HVs) were used as controls. CsA dependency was defined as two or more relapses of anemia (in the PRCA patients) or pancytopenia (in the AA patients) in association with a dose reduction or the cessation of CsA, which had occurred after more than 1 year of therapy, followed by a good response to CsA. After obtaining informed consent, 10 ml of PB was collected from these patients and the HVs using EDTA-coated tubes. The PB was then subjected to mononuclear cell (MC) isolation using density gradient medium (Lymphoprep™, Norway). All of the PB samples were analyzed within 8 h after sampling. This study protocol (No. 287) was approved by the Ethics Committee for Human Genome/Gene Analysis Research at Kanazawa University Graduate School of Medical Science. Informed consent was obtained from all individual participants included in the study.
Cell sorting
PBMCs from HVs were stained with fluorochrome-labeled antibodies (Abs) specific for CD4 (BD Bioscience), CD45RA (BD Bioscience), CD25 (BD Bioscience), CD127 (eBioscience), CCR7 (R&D), and IL-1RI (R&D For the analysis of cytokine production by the Treg subsets, stimulated PBMCs were stained with Abs specific to surface markers, including CD3 and CD4, and then fixed/ permeabilized with a FoxP3 Staining Buffer Set (eBioscience), and stained with Abs specific to intracellular proteins, including Helios, FoxP3, IL-2 (BD Bioscience), IL-17, and INF-γ.
For the measurement of the different Th subsets, PBMCs were stimulated by phorbol myristate acetate (PMA; 50 ng/ml, Sigma-Aldrich) and ionomycin (1 μg/ml, Sigma-Aldrich) in the presence of Golgi Stop (0.75 μl/ml, BD Bioscience) in a tissue culture incubator for 4 h, and the cells were then washed and stained with fluorescence-labeled anti-CD3 and anti-CD4 Abs and analyzed by FCM to determine the percentage of CD3 + CD4 + T cells that were positive for cytoplasmic INF-γ + (Th1, BD Bioscience), IL-4 + (Th2, eBioscience), and IL-17 + (Th17, eBioscience) cells [14] .
The assessment of the proliferation and suppressive function of Tregs
Ex vivo-sorted CD4 + T cell populations were labeled with carboxyfluorescein succinimidyl ester (CFSE; 2.5 μM; Invitrogen), stimulated with Dynabeads® Human TActivator CD3/CD28 (Life Technology) at a cell/bead ratio of 4:1, as described previously [14] 
Statistical analysis
Statistical comparisons of the various lymphocyte subsets were performed using a paired t test or the Mann-Whitney U test. The GraphPad Prism software program (version 5 for Windows, San Diego, CA, USA) was used for the statistical analyses.
Results
The definition of the Treg subsets by flow cytometry with anti-Helios and anti-FoxP3 antibodies accounted for 6.5 ± 1.6 and 2.0 ± 0.6 % of the CD4 + T cells of HVs (Fig. 1a) . Helios − Tregs produced higher amounts of IL-2, IL-17, and IFN-γ than Helios + Tregs (Fig. 1b) . This finding was consistent with previous reports [14] [15] [16] [17] . Both subsets highly expressed CTLA4, CCR4 and contained approximately 12 % Ki67 + cells, indicating that the two T cell subsets were activated in vivo (Fig. S1 ). The proportion of (Fig. 2c, d) .
A decreased percentage and absolute Treg count in PRCA and AA patients
The percentage and absolute counts of Helios + Tregs in PRCA patients were significantly lower than those in HVs including two untreated PRCA patients (3.5 ± 0.2 vs 6.5 ± 1.6 % and 0.0179 ± 0.0075 × 10 9 vs 0.0531 ± 0.0211 × 10 9 /l , respectively), 10 convalescent PRCA patients who were undergoing CsA treatment (3.9 ± 1.6 vs 6.5 ± 1.6 %, P < 0.0001 and 0.0161 ± 0.0070 × 10 9 vs 0.0531 ± 0.0211 × 10 9 /l, P < 0.0001), and four CsA-dependent PRCA patients (4.1 ± 1.9 vs 6.5 ± 1.6 %, P = 0.0261 and 0.0158 ± 0.0102 × 10 9 vs 0.0531 ± 0.0211 × 10 9 /l, P = 0.0021, Fig. 3a , b and Table S1 ). A similar decrease in the percentage of Tregs was observed in the untreated AA patients and the CsA-dependent AA patients, but not in the convalescent AA patients who were undergoing CsA treatment or in the AA patients who were in remission after the cessation of CsA treatment. Of note, the Helios + Treg percentages of the CsA-treated convalescent PRCA patients were significantly lower than those of the CsA-treated convalescent AA patients (3.9 ± 1.6 vs 5.7 ± 0.9 %, P = 0.0370) (Fig. 3b) . With the exception of the convalescent PRCA patients, who had a significantly lower percentage of Helios − Tregs than the HVs, the percentages of Helios − Tregs were similar among the PRCA and AA patients and the HVs (Fig. S2) . The absolute Helios − Treg counts in the convalescent PRCA patients, the CsA-dependent PRCA patients, and the CsA-dependent AA patients were also significantly lower than the counts in the HVs (Fig. S2 ). The − Tregs with a representative scattergram from 6 HVs (b). *, P < 0.05; **, P < 0.01; ***, P < 0.001 percentages of Ki67-positive cells in Helios + Tregs were similar among the PRCA patients (untreated, 13.4 ± 7.4 %; convalescent, 13.4 ± 6.3 %; CsA dependent, 11.8 ± 4.3 %), the AA patients who were in remission (13.8 ± 2.9 %), and the HVs (12.5 ± 2.7 %) while the Ki67-positive cell percentages in the untreated AA (7.4 ± 1.5 %, P = 0.0022) and in the CsAdependent AA (8.6 ± 0.6 %, P = 0.0238) patients were significantly lower than the percentages in the HVs (Fig. 3c) . high activated Tregs in all of the three subsets of PRCA patients tended to be lower than those in HVs while the percentages of CD45RA
−
FoxP3
low cytokineproducing non-Tregs in the three subsets were higher than those of HVs (Fig. 3e) . Representative scattergrams of an HV, a PRCA patient, and an AA patient are shown in Fig. 3d [18] . Among the AA patients, the activated Treg percentages of the untreated AA patients, the convalescent AA patients, and the CsA-dependent AA patients were significantly lower than those in HVs while the AA patients who were in remission had a similar percentage of activated Tregs (25.3 ± 8.6 %) to HVs (23.9 ± 7.4 %). The percentages of cytokine-producing non-Tregs in untreated AA patients, CsA-dependent AA patients, and AA patients who were in remission were significantly higher than in HVs (Fig. 3e) .
The T helper cell subsets in PRCA and AA patients
The ratios of CD4 + T cells to CD8 + T cells were significantly lower in PRCA patients than in HVs (Fig. S3a) . In PRCA patients, the CD4 + T cell counts of convalescent and CsAdependent patients were significantly lower than in HVs (Fig. S3b) . In AA patients, the CD4 + T cell counts in CsAdependent AA patients and AA patients who were in remission were significantly lower than in HVs, while those of untreated AA and convalescent AA patients were comparable to HVs (Fig. S3b) .
In contrast to the decreased percentages of Tregs, the percentages of Th1, Th2, and Th17 cells in all of the PRCA subsets were comparable to those in HVs (Fig. S4a, b) . In AA patients, the percentages of Th1 and Th2 cells in the four different groups were also comparable to HVs, while the percentages of Th17 cells in untreated AA (3.1 ± 2.0 %, P = 0.0422) and CsA-dependent AA (2.9 ± 1.6 %, P = 0.0392) patients were significantly higher than in HVs (1.6 ± 0.7 %), (Fig. S4a, b) . The absolute counts of Th1, Th2, and Th17 cells were significantly lower than in HVs due to the decreased CD4 + T cell counts in PRCA patients (Fig. S3c) . In contrast, the untreated AA patients showed a significant increase in their Th1 and Th17 cell counts in comparison to HVs while the Th1 and Th17 cell counts in other AA patients were comparable or lower than those in HVs due to their decreased CD4 + T cell counts (Fig. S4b) .
The ratios of each Th subset to Tregs
As a result of the decrease in the percentage of Tregs, the Th1/ Treg and Th2/Treg ratios of the CsA-dependent PRCA patients (7.38 ± 2.58, P = 0.0145 and 1.27 ± 0.37, P = 0.0414) and the Th1/Treg ratio of convalescent CsA-treated PRCA patients (7.49 ± 4.64, P = 0.0004) were significantly higher than those of HVs (3.33 ± 0.90, 0.83 ± 0.24) (Fig. 3f and Table S1 ). The Th1/Treg, Th2/Treg, and Th17/Treg ratios of untreated PRCA patients tended to be higher than those of HVs. Similarly, untreated AA patients had significantly increased Th1/Treg (6.18 ± 2.35, P = 0.0007), Th2/Treg (1.36 ± 0.72, P = 0.0214), and Th17/Treg (0.69 ± 0.33, P = 0.0008) ratios and CsA-dependent AA patients had significantly increased Th1/Treg (8.94 ± 4.06, P = 0.0014) and Th17/Treg (0.81 ± 0.33, P = 0.0005) ratios in comparison to HVs. In contrast to untreated AA and CsA-dependent AA patients, convalescent CsA-treated AA patients and AA patients who were remission had similar Th1/Treg, Th2/Treg, and Th17/Treg ratios to HVs (Fig. 3f) .
The effect of CsA on Tconv proliferation
The normal blood cell counts and lower Treg counts of CsAtreated PRCA patients who were in remission and CsAdependent AA patients may indicate that, in the blood, CsA complements the inadequate suppression of the Tconv function by Tregs due to their decreased number. We therefore tested the effect of CsA on the proliferation of Tconvs using a CFSE assay. As shown in Fig. 4 , CsA inhibited Tconv proliferation in a dose-dependent manner. CsA at concentrations of 50 and 100 ng/ml, which can be achieved in blood by the administration of 2-3 mg/kg of CsA, inhibited the proliferation of Tconvs by 25.9 and 50.4 %, respectively (Fig. 4a, b) .
Discussion
Several studies have focused on the role of Tregs in the pathophysiology autoimmune diseases such as AA, type 1 ; Conval, n = 10 [17.4 ± 9.9 %, P = 0.0091; 15.1 ± 9.3 %, P = 0.0063, and 67.5 ± 7.6 %, P < 0.0001]; and CsA-D, n = 4 [10.6 ± 7.8 %, P = 0.0129; 13.3 ± 10.2 %, P = 0.0511, and 76.1 ± 17.3 %, P = 0.0081]), and 29 AA patients (UT, n = 9 [15.5 ± 11.2 %, P = 0.0224; 13.5 ± 7.3 %, P = 0.0012, and 71.0 ± 12.8 %, P < 0.0001]; Conval, n = 5 [30.4 ± 11.4 %, P = 0.3339; 15.0 ± 6.5 %, P = 0.0320, and 54.6 ± 11.7 %, P = 0.2679]; CsA-D, n = 6 [20.1 ± 12.6, P = 0.5666; 12.5 ± 3.4 %, P = 0.0009, and 67.4 ± 10.9 %, P = 0.0014]; and Rem, n = 9 [10.4 ± 5.9 %, P = 0.0002; 25.3 ± 8.6 %, P = 0.7769, and 64.3 ± 9.0 %, P = 0.0008]) were analyzed by FCM. Each of the Treg subsets in PRCA and AA patients was compared to a similar subset of HVs (e). The ratios of Th1/Treg, Th2/Treg, and Th17/Treg in 16 PRCA patients (UT, n = 2; Conval, n = 10; and CsA-D, n = 4) and 26 AA patients (UT, n = 9; Conval, n = 5; CsA-D, n = 6; and Rem, n = 6) were compared to those of 32 HVs. The ratios are shown (f). *P < 0.05; **P < 0.01; ***P < 0.001 d i a b e t e s , a n d p s o r i a s i s a n d h a v e f o u n d t h a t CD4 + CD25 + FoxP3 + Treg numbers were profoundly decreased in patients with active disease [19] [20] [21] [22] [23] . Previous studies on bone marrow failure syndromes revealed a decrease in the CD4
+ Treg number, an impaired suppressive function of Tregs on Tconvs, and the reduced trafficking of Tregs to the BM in patients with AA [12, 13] . However, it remains unclear which phenotype best represents functional T r e g s i n h u m a n s . We d e f i n e d T r e g c e l l s a s
CD4
+ FoxP3 + Helios + T cells because Helios, a member of the Ikaros gene family, is expressed by 70-80 % of human FoxP3 + T cells and is known to be a good marker for natural Tregs [24, 25] . When we determined the phenotype of the CD4 + T cells of HVs and PRCA patients using anti-C D 4 5 R A a n d a n t i -F o x P 3 A b s , w e f o u n d t h a t CD45RA − FoxP3 low cells (cytokine-producing non-Tregs) accounted for 50.5 ± 7.5 % of FoxP3 + cells in HVs, 67.5-76.1 % in PRCA patients, and 54.6-67.4 % in AA patients; however, the border between CD45RA − FoxP3 high cells and CD45RA
−
FoxP3
low cells was sometimes unclear in patients with PRCA and AA due to their decreased Treg percentages (Fig. 3d) . Moreover, not all cytokine-producing non-Treg cells are reported to be cytokine-producing cells [16, 18] . In contrast, anti-Helios mAbs clearly divided FoxP3 + cells into Helios + and Helios − subpopulations (Fig. 1a) , and Helios + Treg cells rarely produced many cytokines in comparison to Helios − Treg cells (Fig. 1b) These results were in agreement with a previous study which found that the Helios − Treg subpopulation harbors a larger population of non-suppressive clones than the Helios + cell subset [17] . These results validated the use of a phenotype Helios + as a marker of functional Tregs. Our study revealed, for the first time, a significant decrease in the percentage and in the absolute count of Helios + Tregs in PRCA patients regardless of CsA treatment status. Unlike AA patients, lymphopoiesis is not affected by a decrease in the number of hematopoietic stem cells in PRCA patients where only the erythroid precursors are diminished. Our results therefore substantiated that a decrease in the Treg percentage and/or an increase in the Th/Treg ratio contributes to failed hematopoiesis. One may argue that in CsA-treated PRCA patients who are in remission, the marked decrease in Tregs may be caused by the long-term administration of CsA. Several studies have shown the suppressive effects of CsA on Treg numbers [26, 27] . However, in patients with atopic dermatitis, low-dose CsA treatment (2 mg/kg/ day) results in an increase in the number of peripheral Tregs without affecting the CD3 + , CD4 + , and CD8 + cell populations [28, 29] . Similarly, a lower dose of CsA has been shown to promote Treg development in a rat cardiac allograft model [30] . A recent study also showed that clinically relevant CsA concentrations increased Treg numbers in vitro [31] . Moreover, a decrease in the Helios + Treg percentage was also observed in PRCA and AA patients before CsA therapy, and the normal Treg percentage was maintained in convalescent CsAtreated AA patients. These findings suggest that a decreased in Treg count is related to the disease activity of immune-mediated bone marrow failure.
A striking difference in the response of PRCA and AA patients to CsA was the extent of Treg recovery in association with hematologic recovery. Unlike convalescent CsA-treated AA patients, the Treg percentage and the Th1/Treg ratio remained abnormal in the PRCA patients who responded to CsA. These findings are compatible with the CsA dependency that most PRCA patients show in the clinical setting. A previous study on the helper T cell subsets of PRCA patients demonstrated an increase in the number of Th2 cells in the active phase and the elevation of theTh1/Th2 ratio concomitant with hematological improvement [32] . Our study revealed no significant differences in the percentages of Th1, Th2, and Th17 cells between the PRCA patients and the HVs; however, the absolute counts of Th1, Th2, and Th17 cells were lower in the PRCA patients than in the HVs due to their low CD4 cell count. The apparent decrease in Tregs resulted in a significant increase in the Th1/Treg in convalescent and CsA-dependent PRCA patients. An imbalance between Ths and Tregs has been implicated in the disease activity of several autoimmune diseases, including rheumatoid arthritis, SLE, and multiple sclerosis [33] [34] [35] [36] . Consistent with previous studies on AA using different Treg markers [12, 20] , the Th1/Treg, Th2/Treg, and Th17/Treg ratios were markedly higher in our patients with active AA than in HVs. These findings suggest that increased Th1/Treg ratios are correlated with the disease activity of PRCA and AA.
Despite the heterogeneity of its pathogenesis, most PRCA patients respond to monotherapy with CsA [7, 37, 38] . The reason for the uniform response to CsA and the target of CsA remain unknown. The results of the present study suggest that the decreased Treg count is an abnormality that is common to PRCA patients and that CsA may complement the role of Tregs in vivo. This hypothesis was substantiated by our in vitro findings: 50-100 ng/ml of CsA effectively inhibited proliferation of Tconv, to a similar degree to the suppression by Tregs to Tconv at ratios of 1/3 and 1/1 of Tregs (Figs. 2d  and 4b ). Blood trough levels of CsA ranging 50-100 ng/ml can be achieved by the administration of 2-3 mg/kg of CsA [28] . A recent study by Philippe et al. demonstrated that an optimal CsA trough blood concentration for the treatment of SAA was 100 ng/ml [39] .
In the management of PRCA and AA patients who respond to IST, physicians often have difficulties in determining when the CsA dose should be tapered off. The persistently high Th1/ Treg ratio of convalescent PRCA patients and the high Th1/ Treg ratios detected in patients with CsA-dependent PRCA or AA may indicate that the patients have not acquired tolerance to the autoimmune attack against hematopoietic cells and that CsA treatment, which potentially complements the role of Tregs, should be continued.
In summary, the current study demonstrated a profound decrease in Helios + Tregs and an increased Th1/Treg ratio in PRCA and AA patients who were responsive to CsA. The decrease in the Treg percentage is a potential therapeutic target in PRCA. Clinical trials of cytokines that are known to augment Treg function [40] [41] [42] [43] are warranted as a curative treatment in patients with immune-mediated BM failure who are responsive to CsA.
